Targeted therapy for HCC using dumbbell-like nanoparticles conjugated to monoclonal antibodies against VEGF and cancer stem cell receptors in mice

Bibliographic Information
Authors: Mansour W.; EL Fedawy S.F.; Atta S.A.; Zarie R.M.; Fouad N.T.A.; Maher S.; Hussein T.M.; Abdel Aziz D.M.; Kamel M.
Journal: Cancer Nanotechnology
Publisher: BioMed Central Ltd
Publication Date: 25 February 2023
Volume / Issue: Volume 14 / Issue 1
Article No.: 14
ISSN: 18686958
DOI: 10.1186/s12645-023-00163-0
Scopus: View on Scopus
Document Type: Article
Access: All Open Access; Gold Open Access; Green Open Access
Authors and Affiliations
Mansour W., Immunology Department, Theodor Bilharz Research Institute, Giza, Egypt; EL Fedawy S.F., Faculty of Medicine, Ain Shams University, Cairo, Egypt; Atta S.A., Immunology Department, Theodor Bilharz Research Institute, Giza, Egypt; Zarie R.M., Immunology Department, Theodor Bilharz Research Institute, Giza, Egypt; Fouad N.T.A., Faculty of Medicine, Ain Shams University, Cairo, Egypt; Maher S., Immunology Department, Theodor Bilharz Research Institute, Giza, Egypt; Hussein T.M., Physiology Department, National Organization for Drug Control and Research Pyramids Branch, Giza, Egypt; Abdel Aziz D.M., Faculty of Medicine, Ain Shams University, Cairo, Egypt; Kamel M., Immunology Department, Theodor Bilharz Research Institute, Giza, Egypt
Abstract
Background: Hepatocellular carcinoma (HCC) is the leading cause of death worldwide. Nanoparticles allow early detection of tumor and delivery of chemotherapeutic drugs to the specific tumor site. This study aimed to assess the therapeutic role of dumbbell-like nanoparticles conjugated with monoclonal antibodies (mAbs) against both vascular endothelial growth factor (VEGF) and cluster of differentiation (CD) 90 (a cancer stem cell marker) in hepatocellular carcinoma experimental model. This study included 100 mice; HCC was induced chemically in 80 male Balb/c mice by diethylnitrosamine (DEN) and 20 mice served as normal control group. Mice were divided into four groups; pathological control group, mAbs-conjugated nanoparticles-treated group, nanoparticles (alone)-treated group and Avastin-treated group. Animals were sacrificed after one and two months of treatment for assessment of HCC response to treatment. Serum samples were collected and analyzed for alfa-feto protein (AFP), Caspase-3, VEGF-A by enzyme-linked immunosorbent assay (ELISA) technique and alanine transaminase (ALT) and aspartate transaminase (AST) by automated analyzer. Liver sections of sacrificed animals were stained with hematoxylin and eosin (H&E) for histopathological assessment. Results: There were highly significant and significant differences (p value < 0.1 and < 0.5) between mAbs-conjugated nanoparticles-treated group and Avastin group, respectively, in comparison to pathological group. Both groups showed a significant decrease in all serum parameters, but mAbs-conjugated nanoparticles-treated group had more potent improvement effect when compared with Avastin group. MAbs-conjugated nanoparticles-treated group also showed the best improvement in liver architecture. Conclusion: Dumbbell-like nanoparticles conjugated to anti-CD90 and Avastin is a novel therapeutic tool for HCC to target cancer stem cells and endothelial cells in the niche of the tumor. © 2023, The Author(s).
Keywords
Avastin; CD90; Hepatocellular carcinoma; Nanoparticles; alanine aminotransferase; antibody conjugate; aspartate aminotransferase; bevacizumab; caspase 3; cell marker; cell receptor; diethylnitrosamine; gold nanoparticle; magnetite nanoparticle; monoclonal antibody; nanoparticle; Thy 1 membrane glycoprotein; vasculotropin; vasculotropin A; animal cell; animal experiment; animal model; animal tissue; Article; cancer stem cell; cause of death; controlled study; drug release; early cancer diagnosis; enzyme linked immunosorbent assay; female; histopathology; in vitro study; liver cell carcinoma; male; mitosis; molecularly targeted therapy; mouse; nonhuman; pH; spectroscopy; transmission electron microscopy
Citation Information
Scopus Citations: 6
For comprehensive information about the Theodor Bilharz Research Institute (TBRI), its institutional activities, scientific and research achievements, clinical and hospital services, and the diverse expertise offered through its 22 specialized research and clinical departments, as well as opportunities for professional training, specialized workshops, and scientific conferences, readers are invited to visit the Institute’s official website.
The website provides regularly updated information on the Institute’s latest news, research activities, scientific initiatives, clinical services, institutional programs, and academic and professional opportunities.
English Website: https://www.tbri.sci.eg/en/
Arabic Website: https://www.tbri.sci.eg/ar/
Prepared and Uploaded by:
Abdalla F. Abdalla
Electronic Portal Unit
